MetaCap

Azitra (AZTR) vs Kiora Pharmaceuticals (KPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZTR+291.52%KPRX-71.53%
+1116%+494%-128%
Oct 7, 20261 yearNov 20, 2026
AZTR+297.84%KPRX-71.65%
+520%+210%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZTR versus KPRX key metrics
MetricAZTRKPRX
Share price$0.5168$0.7202
Market cap$3.13M$3.19M
1-day change-2.75%-12.28%
YTD return—-63.44%
1-year return—-61.49%
5-year return—-99.87%
EPS (TTM)$-12.40$-2.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)-100.00%-100.00%
Net income (latest FY)$-10.96M$-10.84M
52-week high$3.91$2.91
52-week low$0.5086$0.72
Distance from 52-week high-86.78%-75.25%
Analyst consensusbuynone
Avg. price target upside+29.64%+1566.20%
Average volume2.65M35.23K
Shares outstanding6.06M4.42M
Employees1313
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Azitra

AZTR stock →

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

AZTR vs KPRX FAQ

Which is bigger, Azitra or Kiora Pharmaceuticals?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.13M for Azitra (AZTR).

Are Azitra and Kiora Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons